Genetically engineered viral vectors are excellent inducers of strong CD8+ T cell responses, and recent progress in liver-stage malaria vaccine development with ChAd63-MVA vaccination regimens encoding ME-TRAP is very encouraging, with some degree of clinical efficacy in both malaria naïve and pre-exposed individuals1,2. The gene discussed is CD8A; the disease is malaria.